Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-25T03:13:10.007Z Has data issue: false hasContentIssue false
  • English
  • Français

Efecto de la tandospirona sobre la discinesia tardía y los síntomas parkinsonianos

Published online by Cambridge University Press:  12 May 2020

K. Yoshida ,
T. Sugita ,
H. Higuchi  and
Y. Hishikawa
K. Yoshida
Affiliation:
Departamento de Neuropsiquiatría, Universidad Akita, Escuela de Medicina, 1-1-1 Hondo, Akita 010
T. Sugita
Affiliation:
Hospital Yokote Kosei, Akita, Japón
H. Higuchi
Affiliation:
Departamento de Neuropsiquiatría, Universidad Akita, Escuela de Medicina, 1-1-1 Hondo, Akita 010
Y. Hishikawa
Affiliation:
Departamento de Neuropsiquiatría, Universidad Akita, Escuela de Medicina, 1-1-1 Hondo, Akita 010
Get access

Resumen

Los autores examinaron el efecto de la tandospirona sobre la discinesia tardía (DT) y los síntomas parkinsonianos en un estudio abierto. La tandospirona no produjo ningún efecto favorable sobre la DT, pero tuvo un buen efecto sobre los síntomas parkinsonianos.

Keywords

dopamina5-hidroxitriptaminasíntomas parkinsonianostandospironadiscinesia tardía
Type
Informe Clínico
Information
European Psychiatry (Ed. Española) , Volume 6 , Issue 4 , May 1999 , pp. 250 - 252
Copyright
Copyright © European Psychiatric Association 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Goff, DC, Midha, KK, Brotman, AW, McCormick, S, Waites, M, Amico, ET.An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psycho-pharmacol 1991; 11: 193–7.CrossRefGoogle ScholarPubMed
Haggstrom, JE, Gunne, LM, Carlsson, A, Wikstrom, H.Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias. J Neural Transm 1983; 58: 135–42.CrossRefGoogle ScholarPubMed
Hamik, A, Oksenberg, D, Fischette, C, Peroutka, SJ.Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 1990; 28: 99–109.CrossRefGoogle ScholarPubMed
Kapur, S, Remington, G.Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153: 466–76.Google Scholar
McMillen, BA.Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission. J Neural Transm 1985; 64: 1–12.CrossRefGoogle ScholarPubMed
Moss, LE, Neppe, VM, Drevets, WC.Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1993; 13: 204–9.CrossRefGoogle ScholarPubMed
Riblet, LA, Taylor, DP, Eison, MS, Stanton, HC.Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 1982; 43: 11–8.Google ScholarPubMed
Schooler, NR, Kane, JM.Research diagnoses for tardive dyskinesia [letter], Arch Gen Psychiatry 1982; 39: 486–7.Google Scholar